Answers are grounded in this paper and cite their sources.
Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal hematologic disorder treated with complement inhibitors. Currently, patients with suboptimal response to C5 inhibitors may be switched to proximal complement inhibitors, such as pegcetacoplan, danicopan, or iptacopan. However, data on switching strategies between proximal inhibitors remain limited. Results We report the first case of a direct switch from iptacopan to pegcetacoplan without re‐exposure to C5 inhibitors. Conclusion Direct switching between proximal complement inhibitors may represent a feasible and safe strategy, although further validation in larger cohorts is required.
No takes yet. Share an insight, caveat, or question.
Latyshev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: